adplus-dvertising
Connect with us

Investment

SolarWinds (SWI) Investigation Alert: Did You Lose Money on Your Investment? Contact Johnson Fistel Regarding Investigation – Yahoo Finance

Published

 on


TipRanks

Gilead Sciences or Biogen: Which Biotech Stock is a Better Pick for 2021?

An unprecedented pandemic did not stop the US stock market from finishing 2020 on a high note. The S&P 500 ended a highly volatile year at an all time high and overall, was up 16.3%. Meanwhile, several stocks in the healthcare sector fetched attractive returns for investors. However, that list did not include Gilead Sciences and Biogen.Does Wall Street expect these stocks to recover this year? We used TipRanks’ Stock Comparison tool to find out whether analysts see upside potential in Gilead and Biogen and pick the stock offering a better investment opportunity.Gilead Sciences (GILD)Gilead Sciences grabbed headlines last year when its antiviral drug remdesivir (sold under the brand name Veklury) was granted emergency use authorization in May by the US FDA (Food and Drug Administration) for the treatment of COVID-19. In October 2020, remdesivir became the first FDA-approved treatment in the US for COVID-19 patients.The company generated better-than-anticipated results in 3Q mainly due to remdesivir, which generated $873 million in sales and drove a more than 17% rise in overall 3Q revenue to $6.6 billion. Gilead’s 3Q adjusted EPS increased 29% year-over-year to $2.11. (See GILD stock analysis on TipRanks)However, the company trimmed its 2020 revenue forecast to the range of $23 billion-$23.5 billion, from the previous outlook of $23 billion-$25 billion, and cautioned that remdesivir revenue is subject to significant volatility and uncertainty. Also, its hepatitis C virus (HCV) business continues to be under pressure amid the pandemic.Gilead has a strong HIV portfolio, including its lead drug, Biktarvy. Sales from HIV products grew 8% to $4.5 billion in 3Q and accounted for 70% of the company’s overall product sales. That said, there are concerns about sales of HIV drug Truvada due to loss of exclusivity.Meanwhile, the company is strengthening its business through strategic acquisitions in key growth areas like oncology. Last year, Gilead acquired Immunomedics for $21 billion. This acquisition added Trodelvy, an FDA-approved metastatic triple-negative breast cancer treatment, to Gilead’s portfolio. The company also acquired clinical-stage immuno-oncology company Forty Seven for $4.9 billion in 2020. Most recently, Gilead announced an agreement to acquire German biotech MYR GmbH, which is focused on developing therapeutics for the treatment of chronic hepatitis delta virus.Investors were disappointed when Gilead announced in December that it will not pursue the FDA’s approval for filgotinib as a treatment for rheumatoid arthritis in the US, following a meeting with the regulator. The company entered into a new agreement with partner Galapagos, under which, the latter will assume sole responsibility in Europe for filgotinib, where 200 mg and 100 mg doses are approved for the treatment of moderate to severe rheumatoid arthritis, and in all future indications.In reaction to this development, Oppenheimer analyst Hartaj Singh lowered his price target to $100 from $105. However, the analyst reiterated a Buy rating on Gilead as he continues to believe in his thesis of “(1) a dependable remdesivir/other medicines business against SARS-CoV flares, (2) a base business (HIV/oncology/HCV) growing low-single digits over the next couple of years, (3) operating leverage providing greater earnings growth, and (4) a 3-4% dividend yield.”Currently, the rest of the Street is cautiously optimistic, with a Moderate Buy analyst consensus based on 10 Buys, 12 Holds and 1 Sell. The average price target of $74 suggests an upside potential of 27% from current levels. Shares declined 10.4% in 2020.Biogen (BIIB)2020 was a tough year for Biogen, which specializes in treatments for neurological disorders. The company faced a setback in November when the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted against the effectiveness of aducanumab, an investigational antibody for the treatment of Alzheimer’s disease.The news led to a major sell-off in Biogen shares as investors saw aducanumab as a potential blockbuster drug for the company. The Advisory Committee’s recommendations are non-binding for consideration by the FDA and the company disclosed that the FDA will continue the review process, with a decision on aducanumab’s approval to be made by March 7, 2021. (See BIIB stock analysis on TipRanks)To add to investors’ worries, Biogen lost a patent dispute with Mylan in June 2020 for its top-selling multiple sclerosis drug, Tecfidera, which exposes it to competition from Mylan’s generic version. Tecfidera’s revenue fell 15% in 3Q to $953 million, reflecting the impact of multiple generic entrants in the US.Moreover, Biogen’s spinal muscular atrophy drug, Spinraza, is feeling the impact from Roche’s Evrysdi, with sales of the drug declining 10% to $495 million in 3Q. Overall, the company’s 3Q revenue fell 6.2% to $3.4 billion and adjusted EPS declined 3.6% to $8.84. Biogen lowered its full-year revenue outlook to $13.2 billion-$13.4 billion from $13.8 billion-$14.2 billion, assuming “significant erosion of TECFIDERA” in 4Q.  Biogen has been entering into strategic collaborations to gain access to drugs with promising potential. Recently, it announced a $1.5 billion (plus potential milestone payments) deal with Sage Therapeutics to co-develop and sell zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.Following the SAGE deal, Oppenheimer analyst Jay Olson reiterated a Buy rating on Biogen with a $300 price target. Olson explained, “Zuranolone is a potential first-in-class oral therapy for the treatment of MDD and PPD currently in multiple Ph3 studies. Given our view that zuranolone is an active drug and the considerable market opportunity in MDD/PPD, we believe the deal provides BIIB some much-needed revenue growth in the mid-term and better positions BIIB regardless of the aducanumab outcome.”Meanwhile, the Street is sidelined on Biogen with a Hold analyst consensus based on 11 Buys, 13 Holds and 5 Sells. The average price target stands at $293.74, implying a possible upside of 20% in the months ahead. Biogen shares fell 17.5% last year.ConclusionAfter a rocky 2020, the Street’s sentiment looks better for Gilead than Biogen, backed by factors like the company’s HIV portfolio and prospects in oncology. Also, unlike Biogen, Gilead pays dividends and has a dividend yield of 4.67%.To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment

Let’s block ads! (Why?)

300x250x1

728x90x4

Source link

Continue Reading

Investment

BWXT announces $80M investment for plant in Cambridge – CityNews Kitchener

Published

 on

By


BWX Technologies (BWXT) in Cambridge is investing $80-million to expand their nuclear manufacturing plant in Cambridge.

Minister of Energy, Todd Smith, was in the city on Friday to join the company in the announcement.

The investment will create over 200 new skilled and unionized jobs. This is part of the province’s plan to expand affordable and clean nuclear energy to power the economy.

300x250x1

“With shovels in the ground today on new nuclear generation, including the first small modular reactor in the G7, I’m so pleased to see global nuclear manufacturers like BWXT expanding their operations in Cambridge and hiring more Ontario workers,” Smith said. “The benefits of Ontario’s nuclear industry reaches far beyond the stations at Darlington, Pickering and Bruce, and this $80 million investment shows how all communities can help meet Ontario’s growing demand for clean energy, while also securing local investments and creating even more good-paying jobs.”

The added jobs will support BWXT’s existing operations across the province as well as help the sector’s ongoing operations of existing nuclear stations at Darlington, Bruce and Pickering.

“Our expansion comes at a time when we’re supporting our customers in the successful execution of some of the largest clean nuclear energy projects in the world,” John MacQuarrie, President of Commercial Operations at BWXT, said.

“At the same time, the global nuclear industry is increasingly being called upon to mitigate the impacts of climate change and increase energy security and independence. By investing significantly in our Cambridge manufacturing facility, BWXT is further positioning our business to serve our customers to produce more safe, clean and reliable electricity in Canada and abroad.”

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Investment

AI investments will help chip sector to recover: Analyst – Yahoo Finance

Published

 on

By


The semiconductor sector is undergoing a correction as interest rate cut expectations dwindle, prompting concerns about the impact on these high-growth, technology-driven stocks. Wedbush Enterprise Hardware Analyst Matt Bryson joins Yahoo Finance to discuss the dynamics shaping the chip industry.

Bryson acknowledges that the rise of generative AI has been a significant driving force behind the recent success of chip stocks. While he believes that AI is shifting “the way technology works,” he notes it will take time. Due to this, Bryson highlights that “significant investment” will continue to occur in the chip market, fueled by the growth of generative AI applications.

However, Bryson cautions that as interest rates remain elevated, it could “weigh on consumer spending.” Nevertheless, he expresses confidence that the AI revolution “changing the landscape for tech” will likely insulate the sector from the effect of high interest rates, as investors are unwilling to miss out on the “next technology” breakthrough.

300x250x1

For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance.

This post was written by Angel Smith

Video Transcript

BRAD SMITH: As rate cut bets shift, so have moves in one sector, in particular. Shares of AMD and Intel, both down over 15% in the last 30 days. The Philadelphia Semiconductor Index, also known as Sox, dropping over 10% from recent highs, despite a higher rate environment.

Our next guest is still bullish on the sector. Matt Bryson, Wedbush Enterprise Hardware analyst, joins us now. Matt, thanks so much for taking the time here. Walk us through your thesis here, especially, given some of the pullback that we’ve seen recently.

MATT BRYSON: So I think what we’ve seen over the last year or so is that the growth of generative AI has fueled the chip stocks. And the expectation that AI is going to shift everything in the way that technology works.

And I think that at the end of the day, that that thesis will prove out. I think the question is really timing. But the investments that we’ve seen that have lifted NVIDIA, that have lifted AMD, that have lifted the chip stock and sector, in general, the large cloud service providers, building out data centers. I don’t think anything has changed there in the near term.

So when I speak to OEMs, who are making AI servers, when I speak to cloud service providers, there is still significant investment going on in that space. That investment is slated to continue certainly into 2025. And I think, as long as there is this substantial investment, that we will see chip names report strong numbers and guide for strong growth.

SEANA SMITH: Matt, when it comes to the fact that we are in this macroeconomic environment right now, likelihood that rates will be higher for longer here, at least, when you take a look at the expectations, especially following some of the commentary that we got from Fed officials this week, what does that signal more broadly for the AI trade, meaning, is there a reason to be a bit more cautious in this higher for longer rate environment, at least, in the near term?

MATT BRYSON: Yeah. I think certainly from a market perspective, high interest rates weight on the market. Eventually, they weigh on consumer spending. Certainly, for a lot of the chip names, they’re high multiple stocks.

When you think about where there can be more of a reaction or a negative reaction to high interest rates, certainly, it has some impact on those names. But in terms of, again, AI changing the fundamental landscape for tech, I don’t think that high interest rates or low interest rates will change that.

So when you think about Microsoft, Amazon, all of those large data center operators looking at AI, potentially, changing the landscape forever and wanting to make a bet on AI to make sure that they don’t miss that change, I don’t think whether interest rates are low or high are going to really affect their investment.

I think they’re going to go ahead and invest because no one wants to be the guy that missed the next technology wave.

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Investment

If pension funds can't see the case for investing in Canada, why should you? – The Globe and Mail

Published

 on

By


It’s time to ask a rude question: Is Canada still worth investing in?

Before you rush to deliver an appropriately patriotic response, think about the issue for a moment.

A good place to begin is with the federal government’s announcement this week that it is forming a task force under former Bank of Canada governor Stephen Poloz. The task force’s job will be to find ways to encourage Canadian pension funds to invest more of their assets in Canada.

300x250x1

Wooing pension funds has become a high-priority matter for Ottawa because, at the moment, these big institutional investors don’t invest all that much in Canada. The Canada Pension Plan Investment Board, for instance, had a mere 14 per cent of its massive $570-billion portfolio in Canadian assets at the end of its last fiscal year.

Other major Canadian pension plans have similar allocations, especially if you look beyond their holdings of government bonds and consider only their investments in stocks, infrastructure and real assets. When it comes to such risky assets, these big, sophisticated players often see more potential for good returns outside of Canada than at home.

This leads to a simple question: If the CPPIB and other sophisticated investors aren’t overwhelmed by Canada’s investment appeal, why should you and I be?

It’s not as if Canadian stocks have a record of outstanding success. Over the past decade, they have lagged far behind the juicy returns of the U.S.-based S&P 500.

To be fair, other countries have also fallen short of Wall Street’s glorious run. Still, Canadian stocks have only a middling record over the past 10 years even when measured against other non-U.S. peers. They have trailed French and Japanese stocks and achieved much the same results as their Australian counterparts. There is no obvious Canadian edge.

There are also no obvious reasons to think this middle-of-the-pack record will suddenly improve.

A generation of mismanagement by both major Canadian political parties has spawned a housing crisis and kneecapped productivity growth. It has driven household debt burdens to scary levels.

Policy makers appear unwilling to take bold action on many long-standing problems. Interprovincial trade barriers remain scandalously high, supply-managed agriculture continues to coddle inefficient small producers, and tax policy still pushes people to invest in homes rather than in productive enterprises.

From an investor’s perspective, the situation is not that appetizing. A handful of big banks, a cluster of energy producers and a pair of railways dominate Canada’s stock market. They are solid businesses, yes, but they are also mature industries, with less than thrilling growth prospects.

What is largely missing from the Canadian stock scene are big companies with the potential to expand and innovate around the globe. Shopify Inc. SHOP-T and Brookfield Corp. BN-T qualify. After that, the pickings get scarce, especially in areas such as health care, technology and retailing.

So why hold Canadian stocks at all? Four rationales come to mind:

  • Canadian stocks have lower political risk than U.S. stocks, especially in the run-up to this year’s U.S. presidential election. They also are far away from the front lines of any potential European or Asian conflict.
  • They are cheaper than U.S. stocks on many metrics, including price-to-earnings ratios, price-to-book ratios and dividend yields. Scored in terms of these standard market metrics, they are valued more or less in line with European and Japanese stocks, according to Citigroup calculations.
  • Canadian dividends carry some tax advantages and holding reliable Canadian dividend payers means you don’t have to worry about exchange-rate fluctuations.
  • Despite what you may think, Canada’s fiscal situation actually looks relatively benign. Many countries have seen an explosion of debt since the pandemic hit, but our projected deficits are nowhere near as worrisome as those in the United States, China, Italy or Britain, according to International Monetary Fund figures.

How compelling you find these rationales will depend upon your personal circumstances. Based strictly on the numbers, Canadian stocks look like ho-hum investments – they’re reasonable enough places to put your money, but they fail to stand out compared with what is available globally.

Canadians, though, have always displayed a striking fondness for homebrew. Canadian stocks make up only a smidgen of the global market – about 3 per cent, to be precise – but Canadians typically pour more than half of their total stock market investments into Canadian stocks, according to the International Monetary Fund. This home market bias is hard to justify on any rational basis.

What is more reasonable? Vanguard Canada crunched the historical data in a report last year and concluded that Canadian investors could achieve the best balance between risk and reward by devoting only about 30 per cent of their equity holdings to Canadian stocks.

This seems to be more or less in line with what many Canadian pension funds currently do. They have about half their portfolio in equities, so devoting 30 per cent of that half to domestic stocks works out to holding about 15 per cent of their total portfolio in Canadian equities.

That modest allocation to Canadian stocks is a useful model for Canadian investors of all sizes. And if Ottawa doesn’t like it? Perhaps it could do more to make Canada an attractive investment destination.

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Trending